DIACEUTICS PLC

Share Issue/Capital Change • Apr 5, 2022

National Storage Mechanism | Additional information

RNS Number : 3696H

Diaceutics PLC

05 April 2022

5 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Conversion of Convertible Loan Notes & Total Voting Rights

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company, announces that a holder ("Noteholder") of £100,000 of convertible loan notes issued by Diaceutics on 15 October 2018 ("CLN's"), has elected to convert the loan note principal plus interest accrued over the period into 233,508 ordinary shares of £0.002 each ("Ordinary Shares"), at a 25% discount to the Company's IPO price in accordance with the instrument's terms, being a price of £0.57 per Ordinary Share.

In accordance with the authority granted to the Directors at the Annual General Meeting of shareholders on 19 May 2021, 233,508 new Ordinary Shares (the "Conversion Shares") will be issued to the Noteholder. Application has been made for the admission of the Conversion Shares to trading on AIM, with such admission expected to become effective on 8 April 2022 ("Admission").

The Company will have no outstanding convertible loan notes on the allotment of the above Conversion Shares.

Following Admission, the total issued share capital of the Company will consist of 84,302,431 Ordinary Shares of £0.002 each. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBSGDSSSGDGDU